Scandinavian journal of gastroenterology
-
Scand. J. Gastroenterol. · Jun 1989
Clinical Trial Controlled Clinical TrialChronic non-specific diarrhea of infancy successfully treated with trimethoprim-sulfamethoxazole.
Fifteen children who fulfilled the criteria of chronic non-specific diarrhea of infancy were evaluated for intestinal bacterial overgrowth. In 10 of 11 successfully investigated children we found bacterial overgrowth of the small intestine by upper respiratory tract microflora. In 9 of 10 children (group I) treated with trimethoprim-sulfamethoxazole the diarrhea ceased immediately, whereas in all children in group II (n = 5; 3 children excluded because of growth of Yersinia enterocolitica) treated with low-lactose diet the diarrhea persisted (p = 0.004). The results indicate that bacterial overgrowth of the small intestine by upper respiratory tract microflora may be a cause of chronic non-specific diarrhea and that this diarrhea may be successfully treated with trimethoprim-sulfamethoxazole.
-
Scand. J. Gastroenterol. · Dec 1988
Comparative StudySerum selenium and zinc concentrations in morbid obesity. Comparison of controls and patients with jejunoileal bypass.
The concentrations of serum selenium and zinc (both in micromoles per litre) were determined in 18 patients 5-12 years after jejunoileal bypass and in 13 controls with untreated morbid obesity. Selenium concentrations were significantly lower in the operated patients than among controls, whereas there was no significant difference with regard to zinc. Ninety-five per cent confidence limits for the median difference between pre- and post-operative concentrations were 0.03-0.41 with regard to selenium and -0.3 to 2.7 with regard to zinc. Even though little is known about the clinical consequences of chronic selenium deficiency, substitution might prove beneficial.
-
Scand. J. Gastroenterol. · Apr 1988
Randomized Controlled Trial Clinical TrialCimetidine responders in non-ulcer dyspepsia.
The effect of cimetidine and placebo was examined in 123 patients with non-ulcer dyspepsia (NUD) by means of a 12-day multi-crossover model with 5 regular interchanges between cimetidine and placebo. The evaluation of effect in individual patients was based on the number of times cimetidine was associated with less symptoms than the preceding or following placebo period. If cimetidine had no effect, the probability of being defined as a cimetidine responder was 25%. ⋯ The ability of symptoms selected by stepwise logistic regression to predict response to cimetidine showed at best a sensitivity of 75% and a specificity of about 65%. No differences were found between R and NR with regard to acid secretion, endoscopic and histologic findings, or the result of an acid perfusion test. The present study supports the existence of a subgroup of cimetidine responders among patients with NUD characterized by symptoms suggestive of gastroesophageal reflux disease in the absence of confirmatory objective evidence.
-
Scand. J. Gastroenterol. · Dec 1985
Randomized Controlled Trial Clinical TrialCoeliac plexus block versus pancreaticogastrostomy for pain in chronic pancreatitis. A controlled randomized trial.
Seventeen patients with chronic pancreatitis and dilated pancreatic ducts were randomly allocated to coeliac plexus block or pancreaticogastrostomy. The number of patients with pain relief after coeliac plexus block and pancreaticogastrostomy did not differ at discharge. ⋯ Operation decreased pancreatic tissue pressure significantly. This pressure decrease is believed to explain pain relief.
-
Scand. J. Gastroenterol. · Jan 1985
Clinical Trial Controlled Clinical TrialThe effect of cimetidine in non-ulcer dyspepsia. Experience with a multi-cross-over model.
The symptomatic effect of cimetidine was examined in 27 patients with non-ulcer dyspepsia (NUD) by means of a multi-cross-over model (MCO model) for testing the symptomatic effect of drugs in individual patients. None of the patients showed an ulcer at the time, but 20 patients had evidence of previous peptic ulcer disease. The variant of the MCO model used included six treatment periods and three regular interchanges between cimetidine and placebo. ⋯ The chance of getting an X score of 5 when cimetidine is not better than placebo is about 9%. Accordingly, the risk of being wrong when defining these five patients as cimetidine responders is 9%. The present study confirms that the MCO model may identify individual cimetidine responders among patients with NUD.